EMA Authorised: Qinlock (ripretinib) — Deciphera Pharmaceuticals (Netherlands) B.V.

View source ↗

Summary

Qinlock (ripretinib) has been authorised in the EU for gastrointestinal stromal tumors, with orphan medicinal product designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• QINLOCK (ripretinib)

Snippet

Status: Authorised. Therapeutic area: Gastrointestinal Stromal Tumors. MAH: Deciphera Pharmaceuticals (Netherlands) B.V.. Decision date: 29/07/2026. Orphan medicine